{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:14:34Z","timestamp":1778087674428,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1053\/j.ajkd.2025.12.002","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:31:33Z","timestamp":1776760293000},"page":"597-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)\u2013Associated Vasculitis"],"prefix":"10.1053","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2271-500X","authenticated-orcid":false,"given":"Salem","family":"Almaani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib1","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update","volume":"10","author":"Almaani","year":"2021","journal-title":"J Clin Med"},{"issue":"3S","key":"10.1053\/j.ajkd.2025.12.002_bib2","first-page":"S71","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1681\/ASN.0000000000000274","article-title":"The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials","volume":"35","author":"Bate","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/ki.2014.424","article-title":"Update on endocarditis-associated glomerulonephritis","volume":"87","author":"Boils","year":"2015","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2025.12.002_bib5","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.12.002_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1681\/ASN.0000000749","article-title":"Antineutrophil cytoplasmic antibodies (ANCAs): role in diagnosis, disease monitoring, and prognosis","volume":"36","author":"Wyatt","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2025.12.002_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/acr.24633","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of polyarteritis nodosa","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/acr2.11274","article-title":"Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody-associated vasculitis: systematic review and meta-analysis","volume":"3","author":"B\u00e9nard","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.12.002_bib18","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3899\/jrheum.201330","article-title":"ANCA-associated vasculitis management in the United States: data from the Rheumatology Informatics System for Effectiveness (RISE) Registry","volume":"48","author":"Wallace","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2025.12.002_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1053\/j.ajkd.2025.12.002_bib22","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2025.12.002_bib23","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2025.12.002_bib25","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.12.002_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.kint.2023.02.029","article-title":"Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis","volume":"103","author":"Benichou","year":"2023","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2215\/CJN.00480115","article-title":"Outcome and treatment of elderly patients with ANCA-associated vasculitis","volume":"10","author":"Weiner","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.12.002_bib31","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","article-title":"Long-term outcomes in elderly patients with ANCA-associated vasculitis","volume":"59","author":"McGovern","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1053\/j.ajkd.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2025.12.002_bib34","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2215\/CJN.03190321","article-title":"Disease activity and adverse events in patients with ANCA-associated vasculitides undergoing long-term dialysis","volume":"16","author":"Kauffmann","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.12.002_bib35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"New Engl J Med"},{"issue":"21","key":"10.1053\/j.ajkd.2025.12.002_bib37","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.ajkd.2025.12.002_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/rheumatology\/kez001","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib39","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ekir.2025.03.009","article-title":"Long-term follow-up of a glucocorticoid minimizing regimen for the treatment of severe antineutrophil cytoplasmic autoantibody\u2013associated vasculitis","volume":"10","author":"McAdoo","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2025.12.002_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib41","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2025.12.002_bib42","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1164\/rccm.202308-1426OC","article-title":"Alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: results of an international randomized controlled trial (PEXIVAS)","volume":"209","author":"Fussner","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.12.002_bib43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival\u2014frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2025.12.002_bib45","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2025.12.002_bib46","doi-asserted-by":"crossref","first-page":"i88","DOI":"10.1093\/rheumatology\/keae490","article-title":"Highlights from the plenary session: advances in treatment (I)","volume":"64","author":"Smith","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1053\/j.ajkd.2025.12.002_bib47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.12.002_bib48","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2025.12.002_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf070","article-title":"Cardiovascular involvement in ANCA-associated vasculitis","author":"Sarmad","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1053\/j.ajkd.2025.12.002_bib52","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.12.002_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.12.002_bib54","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib55","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/keaa667","article-title":"Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies","volume":"60","author":"He","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib56","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"10.1053\/j.ajkd.2025.12.002_bib57","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"New Engl J Med"},{"issue":"21","key":"10.1053\/j.ajkd.2025.12.002_bib58","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.ajkd.2025.12.002_bib59","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.12.002_bib60","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2025.12.002_bib61","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1053\/j.ajkd.2025.12.002_bib62","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ccm.2019.05.012","article-title":"Update on the management of respiratory manifestations of the antineutrophil cytoplasmic antibodies-associated vasculitides","volume":"40","author":"Thompson","year":"2019","journal-title":"Clin Chest Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.12.002_bib64","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1093\/ndt\/gfp347","article-title":"Renal transplantation in systemic vasculitis: when is it safe?","volume":"24","author":"Little","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.12.002_bib65","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ctr.12084","article-title":"Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation","volume":"27","author":"Marco","year":"2013","journal-title":"Clin Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:55:14Z","timestamp":1778086514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626007250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0272638626007250"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.12.002","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)\u2013Associated Vasculitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}